One of the companies working on a coronavirus vaccine, Vaxart, not only was served with a subpoena in July for allegedly misrepresenting its role with the government in Operation Warp Speed, but is now being sued by investors for it.
The problems stem from a June press release in which Vaxart said it was part of Operation Warp Speed. The announcement propelled its stock prices from $3 a share to $17, earning hedge fund Armistice Capital more than $200 million when the agency sold its shares.
Since then Vaxart has been involved in a series of back-and-forth court filings; its stock price as of October 16, 2020, was down to $6 a share.